Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
64.5M
-
Number of holders
-
52
-
Total 13F shares, excl. options
-
16.3M
-
Shares change
-
+16.3M
-
Total reported value, excl. options
-
$429M
-
Value change
-
+$429M
-
Number of buys
-
52
-
Price
-
$26.29
Significant Holders of Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) as of Q3 2020
52 filings reported holding INZY - Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share as of Q3 2020.
Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.3M shares
of 64.5M outstanding shares and own 25.27% of the company stock.
Largest 10 shareholders include Novo Holdings A/S (2.57M shares), NEA Management Company, LLC (2.44M shares), Sofinnova Investments, Inc. (2.03M shares), RA CAPITAL MANAGEMENT, L.P. (2M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.15M shares), CHI Advisors LLC (1.01M shares), Rock Springs Capital Management LP (880K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (800K shares), FMR LLC (609K shares), and BlackRock Inc. (501K shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.